Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?

著录项

• 来源
  《Current oncology reports.》 |2020年第6期|共12页
• 作者

  Xi Jing; Ma Cynthia X.;

  展开▼
• 作者单位

  Washington Univ Sch Med Dept Internal Med Sect Med Oncol Div Oncol 660 South Euclid Ave Campus;

  Washington Univ Sch Med Dept Internal Med Sect Med Oncol Div Oncol 660 South Euclid Ave Campus;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 肿瘤学;
• 关键词

  Metastatic breast cancer (MBC); Hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer; Estrogen receptor-positive (ER plus ) breast cancer; CDK4; 6 inhibitor; Endocrine therapy; Biomarkers; Sequencing of therapy; Resistance mechanisms; Clinical trials; PI3K inhibitor; mTOR inhibitor; FGFR inhibitor; CDK inhibitor; Aurora kinase inhibitor; RB1; PIK3CA; ESR1; Palbociclib; Abemaciclib; Ribociclib; Alpelisib; Everolimus; Selective estrogen receptor downregulator (SERD); Fulvestrant; Aromatase inhibitor; Targeted therapy;

  机译：转移性乳腺癌（MBC）;激素受体阳性（HR +）和Her2阴性（HER2-）乳腺癌;雌激素受体阳性（ER加）乳腺癌;CDK4;6抑制剂;内分泌治疗;生物标志物;治疗测序;抗性机制;临床试验;PI3K抑制剂;MTOR抑制剂;FGFR抑制剂;Aurora激酶抑制剂;RB1;PIK3CA;ESR1;PALBOCICLIB;eBEMACICLIB;亚丙杆菌;艾尔氏菌属;富洛米司;氟虫酸;氟紫外酶抑制剂;有针对性的治疗;